Brochure
Protein and Antibody Drug CDMO Service – Developing Complex Molecules Easily
Protein & Antibody Drug
CDMO Service
Developing Complex Molecules Easily
ProBio
Global CDMO in biologics and
advanced therapies
Leader in complex molecule
development
We provide premium
end-to-end service from
discovery to commercialization
with professional solutions and
efficient processes
Developing Complex Molecules Easily
Quality Built From the Very Beginning
Antibody lead generation & lead optimization with strong
track record
Broad selection of In vitro / in vivo pharmacology service
Developability assessment & optimization
Breakthrough to Next Levels of Productivity
Proprietary cell line platform capable to achieve 15g/L#
150+
Process optimization achieved up to 70% reduction in
manufacturing cost
protein & antibody
CMC/CMO projects
Less than $100/g* of mAb
70+
Expertise in Proteins & Bispecifics
IND clearances
Extensive experience in natural proteins, fusion proteins,
symmetric bsAb & asymmetric bsAb
ProBoxTM platform for CQA modification and troubleshooting
Flexible manufacturing scale from 25L to 2000L
4
biologics or medical
devices launched
9
ProBio supports partners
in the license-out projects
(including 2 projects
with buyers from MNCs
Pass EU QP audition
# Data by Dec. 2025
*DS unit price (a. Fed batch process in 2000L SUB, b. 7g/L, 70% yield, c. annual batch
number≥ 20 batches) , including FFS and material cost
Biologics Manufacturing
License
1
Quality Built From the Very Beginning
ProBio’s cutting-edge biologics discovery platform & developability platform deliver
biologics candidate of high quality
2400+
18+
2
antibody discovery
projects
projects in clinical trials
and above
Projects
in the market
3 Technical Campaigns to
Optimize Antibody from
Developability Platform to
Guide CMC Strategy
Get Leads with Good Qualities
Developability and Functionality
Proprietary hybridoma platform
ProSpeedTM single B cell screening
Diversified library for both conven-
tional antibody & sdAb
Ab humanization
Colloidal stability study
Ab affinity maturation
Fc engineering
Molecular integrity study
Stressed stability (high temperature,
low pH, freeze and thaw)
Developability optimization
Developability
Study
Lead
Lead
Optimization
Generation
In Vivo
In Vitro
Pharmacology
Bioassay
Comprehensive Cell-based
In Vivo Pharmacology Platform
to Select Final Candidate
Assays to Narrow Down Leads
Bioassay of mAb-Fab/Fc domain
Bispecific Ab assay
ADC assay
Pharmacodynamics
Pharmacokinetics
Toxicology
CAR-T/NK assay, etc.
Breakthrough to Next Levels of Productivity
ProBio’s high-expressing, robust and well-proven cell line and process
technology ecosystem enables titer as high as 15g/L and saves up to 70% COGS
CHO cells & vectors
Proprietary CHO cells
CHOK1-GenS & CHOK1-ADCC+
(FUT8 knock-out)
Cell culture media
Process development
Proprietary UproCHOTM basal, feed
media & perfusion media developed
for ProBio CHOK1-GenS
Multiple cell culture processes
with titer guarantees
Fed-batch: >5g/L
Intensified Fed-batch: 5~10g/L
Perfusion: 30g/L
Proven to optimize cell growth,
productivity and product quality
when used in CHOK1-GenS
Proprietary high-expressing
pGenHT1.0-UP and ProMax vectors
mAb titer: average 7.5 g/L, up to 15 g/L
bsAb titer: average 7.0 g/L, up to 10 g/L
Process optimization achieved
up to 70% reduction in
manufacturing cost
Performing the highest titer in 27 of
37 (approx. 73%) projects among all
major brands
Recombinant protein titer: average
5.8g/L, up to 14.5g/L
Exhibiting lower Man5 proportion
than other major media brands
# Data by Dec. 2025
2
Expertise in Proteins & Bispecifics
~50% projects delivered are
proteins & bispecific
antibodies
IND clearances for multiple
complex modalities:
Factor VIII, cytokines, fusion
proteins, antibody frag-
ment, KIH, Duobody, scFv
fused to IgG, etc.
Platform process for
Small to large scale DS GMP
manufacturing capacity for
proteins & bispecifics
25L, 50L, 80L, 100L, 200L,
500L, 1000L, 2000L
proteins & bispecifics
In-house process develop-
ment intelligence database
ProBoxTM to empower new
projects
In-house cell line engineering
team to develop assay cell line
and bioassay according to MOA
Protein & Bispecifics Delivered by ProBio
Bispecific Antibody
IgG-like (Fc-related)
Symmetric BsAb Asymmetric BsAb
Non IgG-like (Fab-related)
BsAb Fragments BsAb Conjugates
IgFusionProtein
Fab-Fusion Protein
Fc-Fusion Protein
Recombinant Protein
3
IND-to-BLA GMP Manufacturing Facilities of Global
Quality Standard
Nanjing GMP Manufacturing Capacity
Drug substance manufacturing 2,800L:
6×200L & 3×500L single-use bioreactors
Bio-R&D Center, Nanjing, China
Fill and finish line: vial/PFS/lyo/nasal spray
0.3-20mL high-precision filling
Bio-MFG Center, Nanjing, China
Zhenjiang GMP Manufacturing Capacity
Drug substance manufacturing 19,800L:
8×2,000L single-use bioreactors
Fill and finish line: vial/lyo
Up to filling 17 million vials/year
0.3-20mL high-precision filling
Commercial MFG Center, Zhenjiang, China
Pass EU QP audit 6 times
240+ customer audit
NMPA drug manufacturing license
PAI from BPOM (Badan Pengawas
Obat dan Makanan, Indonesia FDA)
ProBio Protein & Antibody Drug CDMO Service
Late Stage
Pre-clinical/
Development
Early Stage
Clinical
Clinical/
Commercialization
Cell Line Development Service
IND-enabling CMC service
Fed-batch
200~500L Scale Clinical
Process Optimization
Manufacturing
Process Characterization,
Process Validation
Pilot Scale Fill and Finish
Liquid
2000L Scale Commercial
Manufacturing
Commercial Scale Fill and
Finish
Perfusion
Lyophilized powder
PFS
# Data by Dec. 2025
4
ProBio Inc.
Building 9, 311 Pennington Rocky Hill Rd,
Pennington, NJ